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Preliminary and Short Report
During previous observations of the interactions
of various cutaneous neoplasms with various anti-
mitotic agents, it was apparent that some of these
compounds produced a rapid and sometimes
marked alteration in the appearance of basal cell
carcinomas on local (1, 2, 3, 4, 5, 6) and parenteral(7) administration. Consequently, a controlled
study was initiated to determine the nature and
relative degree of the biological changes in basal
cell carcinoma resulting from the topical applica-
tion of several antimitotic agents. Although clini-
cal management of basal cell carcinoma was not
the primary concern of the study, one of the pa-
rameters of the biologic changes studied was the
disappearance of the lesion.
METHODS AND MATERIALS
Initial exploratory studies were carried out to
determine possible toxicity and general nature of
response to the several anti-tumor agents under
consideration. From these agents the group of
compounds listed below were selected for a double
blind study involving 31 lesions.
The following compoundst were dispensed in
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* From the Department of Dermatology, the
Department of Pharmacy, and the Department of
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t The chemical agents were obtained as follows:
5-Fluorouracil through the cooperation of Dr. E.
Miller, Hoffman-La Roche, Inc., Nutley, N.J.;
5-Mercaptouracil and Dimethylurethimine through
the cooperation of Dr. T. Bardos, School of Phar-
macy, State University of New York at Buffalo
and Dr. J. Ambrus, Department of Experimental
Biology, Roswell Park Memorial Institute, Buffalo,
New York; Spiramycin through the cooperation of
Dr. N. Back of the School of Pharmacy, State
University of New York at Buffalo; Actinomycin
D through the cooperation of Drs. J. Scigliano and
A. Osterberg of the Cancer Chemotherapy National
Service Center, National Institutes of Health,
Bethesda, Maryland; Methotrexate through the
rooperation of Dr. J. Rugsegger of the Lederle
Laboratories, Pearl River, N. Y.; Nitrogen Mustard
as Mustagen, Merck Sharp and Dohme, West
Point, Pa.
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Plastibase in the respective concentrations: 0.02%
Actinomycin D, 20% Methotrexate, 20% Spiramy-
cm, 0.005% Nitrogen Mustard, 20% 5-Mercapto-
uracil (AB 050), and 10% Dimethyluret}.uimine(AB 132). 20% 5-Fluorouracil (5-EU) was dis-
pensed in Acid Mantle cream. llJnrnedicated ve-
hicles (Acid Mantle cream and petrolatuin) were
used for controls.
The various concentrations were selected on the
basis of generally established systemic doses, as-
suming uniform distribution in various tissues, and
on the basis of preliminary observations of the
concentrations of the various agents that could
be expected to be used without causing severe
toxic reactions to the normal skin of the study
site. In spite of these precautions in choosing the
concentrations of the agents, the applications were
discontinued in several subjects because of severe
local and/or more widespread reaetions.
The protocol established for this study required
the following criteria as qualifications for inclusion
of a tumor in the study.
1. Nodular basal cell carcinoma without ulcera-
tion.
2. Size of tumor no larger than could be easily
excised and repaired with primary closure (i.e. 1
cm in diameter or less).
3. No previous therapy.
4. Location of tumor at a site that could he
easily excised and repaired by primary closure
without compromising the patient's appearance or
function (excluded nose, naso-labial fold, upper
lip, oral commisure, eyelids, and canthi). In ac-
cordance with the method outlined in the study
protocol, the following procedures were ineluded:
a. Selection of lesion.
b. Photograph of lesion prior to, during, and at
termination of study.
c. Punch biopsy specimen prior to and during the
study and excision biopsy specimen at termination
of study.
d. Administration of agent.
Each agent was tested separately on a random
basis and dispensed in sequence. The agent was
applied every two days under an occlusive dressing
of plastic film for one month. Each application and
dressing change was carried out by a member of
the clinic. The selection of tumors that satisfied
the protocol required exclusion of 90% of the
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basal cell carcinomas admitted for treatment to
this service.
RESULTS
In 4 basal cell carcinomas Actinornycin D was
studied. Three of these tumors decreased very
slightly in size during the applications. The fourth
tumor underwent superficial ulcerations, but was
still grossly evident when the application of
Actinomycin D was stopped. One month after
discontinuation of Actinomycin D the tumor had
been replaced by a smooth intact epithelium. Ex-
cision biopsy specimen of the study site showed a
patchy lymphocytic infiltrate and new collagen
fiber formation without residual basal carcinoma.
In two tumors nitrogen mustard was studied.
Both tumors decreased slightly in size and one
became superficially eroded, but neither disap-
peared.
AB 050 was administered to 8 basal cell carci-
nomas. Six showed eczematization (vesiculation
and crusting) of variable severity of the tumor
and surrounding normal skin. Administration of
AB 050 to 4 of the sites was discontinued because
of the appearance of severe dermatitis. Of the 8
tumors studied, 2 were no longer evident grossly
or by biopsy examination following administra-
tion of AB 050. One of these tumors had been
exposed to AB 050 for only two weeks, adminis-
tration having been stopped because of severe
dermatitis. Excision biopsy specimen showed de-
generation of collagen fibers, intense lymphocytic
infiltration and no tumor. The other tumor that
was eliminated was a very small (3 mm) super-
ficial tumor that gradually decreased in size dur-
ing the application of AB 050. No dermatitis oc-
curred and on cessation of the applications, no
tumor was evident grossly or histologically.
In 3 basal cell carcinomas administration of
Spiramycin was studied. Applications were dis-
continued to all study sites in less than one month
because dermatitis of tumor and surrounding
skin was marked. None of the three tumors was
eradicated.
Methotrexate was administered to two basal cell
carcinomas. Both tumors decreased slightly in size,
one became ulcerated but both were still present
grossly and microscopically after cessation of the
applications.
In six basal cell carcinomas 5-fluorouracil was
studied. In most tumors, erythema became evi-
dent within 24—48 hours. Lymphocytic infiltration
in small patches around blood vessels became
evident within two days. Some tumors increased
slightly in size initially; whether this was due to
spongiosis and/or edema of the corium could not
be determined unequivocally. Following the initial
transient swelling, decrease in tumor size became
marked and progressive. Continued daily applica-
tion of 5-fluorouracil under occlusive dressing pro-
duced increased erythema but did not cause the
severe vesicular dermatitis seen with some of the
other agents. Denudation of the epithelium and
ulceration through the epithelium appeared in
portions of the tumor and usually terminated by
involving the whole surface of the tumor. The
base of the ulceration was soft, presumably because
of necrosis of the tumor that was evident micro-
scopically at that time. Occasionally during the
course of 5-fluorouracil therapy, but generally
after the applications had been discontinued, a
crust formed on the soft ulcerated site. Spontane-
ous exfoliation of the crust left a firm erythe-
matous depressed surface.
During applications of 5-fluorouracil, erytherna
usually appeared in the skin surrounding the tu-
mor. Small areas of denudation, a few millimeters
in size, sometimes appeared in the erythematous
skin surrounding the tumor. Erythema and denu-
dation in the skin around the tumor appeared
later and were less marked than in the tumor.
Five of the six tumors studied were no longer
evident following administration of 5-fluorouracil.
The smooth slightly depressed erythematous sites
all showed similar changes on excision biopsy
section. Many new small collagen fibers were
evident. The increased amount of collagen was
consistent with the appearance of early scar for-
mation. Patches of densely packed lymphocytes
were scattered within the coriuni.
One of the tumors studied with 5-fluorouracil
decreased in size and depth during the applications
so that the study site was flat, but excision biopsy
section revealed nests of viable appearing basal
cell carcinoma in the corium as well as the other
microscopic changes mentioned above.
One basal cell carcinoma was studied with AB
132. Within a few days, severe eczematous derma-
titis appeared in the tumor and surrounding area.
Application of AB 132 was discontinued and the
tumor persisted.
Acid mantle cream was applied to three basal
cell carcinomas and petrolatum was applied to two
basal cell carcinomas with the same regimen as
used for the antimitotic agents. Five tumors were
unchanged after applications and showed no
alteration microscopically.
DISCUSSION
This preliminary study was undertaken to de-
termine which, if any, of several antimitotic agents
would result in measurable biological changes in
basal cell carcinoma. By the time observations on
31 tumors had been accumulated, it became ap-
parent that the behavior of the majority of the
treated tumors differed markedly from the natural
course of basal cell carcinoma.
A reaction to the locally administered agents
was present in 26 of 31 tumors, although there
were considerable differences in the degree of
response. The corresponding 31 excisional biopsy
specimens confirmed microscopically the grossly
apparent reaction in the 26 lesions (80%) and
indicated complete regressions in 25% of tumors.
Therefore the code was broken in order to deter-
mine whether these effects were associated with
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several of the agents under study, or whether
statistical significance for a single agent had been
established. If the tumors were reacting similarly
to several of the compounds, an extension of the
study would be necessary; whereas, if the tumors
were reacting more markedly to one compound
than to the others, the study could be revised for
a more intensive investigation of the active com-
pound. Those tumors on which the investigation
was completed in accordance with the protocol
were evaluated by Chi square analysis to determine
whether one of the agents caused a significantly
greater number of tumor regressions than the
other agents. The difference between the number
of tumor regressions after application of 5-fluoro-
uracil and after application of the controls was
significant at the 5% level (P less than .001). The
difference between the number of tumor regressions
after application of AB 050 and after application
of the controls was not significant at the 5% level.
The controls used for these analyses were the
unmedicated bases and the medicated preparations
other than 5-fluorouracil and ABO5O.
The study was designed to conform with condi-
tions previously found to be suitable for further
clinical studies. The statistical significance estab-
lished for the action of 5-fluorouracil is primarily
relevant for the selected parameters of this proto-
coled study. The lack of established statistical
significance for the activities of the other agents
in this study does not by itself exclude anti-tumor
action against basal cell carcinoma on the part
of these compounds. In fact, each one of the
agents which appeared to be less active than 5-
fluorouracil had anti-tumor activity against basal
cell carcinoma when the conditions were modified.
Thus, topical administration of methotrexate to
multiple superficial basal cell carcinomas was fol-
lowed by complete regression of the lesions follow-
ing an inflammatory response sharply limited to
the site of tumor involvement. Similarly, actino-
mycin D, nitrogen mustard, AB 050 and AB 132
were shown to have anti-tumor activity against
basal cell carcinoma when the conditions of the
study were altered.
In accordance with the objectives of the protocol
for this study, factors such as concentration, pene—
tration, absorption, vascular supply, and rate of
removal, which are of critical pharmacologic im-
portance, have not been specifically considered in
this study.
Definitive or long-range evaluation of the vari-
ous agents was limited by the duration of the
observation period set by the protocol criteria and
rendered nonfeasible on a long term basis by the
need for excisional biopsy studies as the terminat-
ing step of the procedure. On the basis of this
data, however, a more definitive study of 5-fluoro-
uracil was initiated which included evaluation for
protracted periods of observation.
SUMMARY AND CONCLUSIONS
A double blind controlled study on the reaction
of basal cell carcinoma to the local administration
of several antimitotic agents was carried out. Un-
der these experimental conditions, 5-fluorouracil
had significant therapeutic effect as determined by
the incidence of tumor regressions on exeisional
biopsy examination.
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